nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—DPYD—attention deficit hyperactivity disorder	0.0513	0.123	CbGpPWpGaD
Dabigatran etexilate—CES2—cardiovascular system—attention deficit hyperactivity disorder	0.0459	0.0788	CbGeAlD
Dabigatran etexilate—F2—cardiovascular system—attention deficit hyperactivity disorder	0.0411	0.0706	CbGeAlD
Dabigatran etexilate—CES1—cardiovascular system—attention deficit hyperactivity disorder	0.0378	0.0649	CbGeAlD
Dabigatran etexilate—CES2—midbrain—attention deficit hyperactivity disorder	0.0358	0.0615	CbGeAlD
Dabigatran etexilate—NQO2—midbrain—attention deficit hyperactivity disorder	0.032	0.055	CbGeAlD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—DPYD—attention deficit hyperactivity disorder	0.0303	0.0724	CbGpPWpGaD
Dabigatran etexilate—CES2—nervous system—attention deficit hyperactivity disorder	0.0294	0.0506	CbGeAlD
Dabigatran etexilate—CES2—central nervous system—attention deficit hyperactivity disorder	0.0283	0.0487	CbGeAlD
Dabigatran etexilate—CES2—cerebellum—attention deficit hyperactivity disorder	0.0277	0.0476	CbGeAlD
Dabigatran etexilate—F2—nervous system—attention deficit hyperactivity disorder	0.0264	0.0453	CbGeAlD
Dabigatran etexilate—NQO2—nervous system—attention deficit hyperactivity disorder	0.0263	0.0452	CbGeAlD
Dabigatran etexilate—F2—central nervous system—attention deficit hyperactivity disorder	0.0254	0.0437	CbGeAlD
Dabigatran etexilate—NQO2—central nervous system—attention deficit hyperactivity disorder	0.0253	0.0435	CbGeAlD
Dabigatran etexilate—F2—Platelet Aggregation (Plug Formation)—ADRA2C—attention deficit hyperactivity disorder	0.025	0.0599	CbGpPWpGaD
Dabigatran etexilate—NQO2—cerebellum—attention deficit hyperactivity disorder	0.0248	0.0425	CbGeAlD
Dabigatran etexilate—CES1—nervous system—attention deficit hyperactivity disorder	0.0242	0.0416	CbGeAlD
Dabigatran etexilate—CES1—central nervous system—attention deficit hyperactivity disorder	0.0233	0.0401	CbGeAlD
Dabigatran etexilate—CES2—brain—attention deficit hyperactivity disorder	0.0225	0.0386	CbGeAlD
Dabigatran etexilate—F2—brain—attention deficit hyperactivity disorder	0.0202	0.0347	CbGeAlD
Dabigatran etexilate—NQO2—brain—attention deficit hyperactivity disorder	0.0201	0.0345	CbGeAlD
Dabigatran etexilate—CES1—brain—attention deficit hyperactivity disorder	0.0185	0.0318	CbGeAlD
Dabigatran etexilate—UGT2B7—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.0174	0.0416	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Estrogen metabolism—COMT—attention deficit hyperactivity disorder	0.0141	0.0338	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet Aggregation (Plug Formation)—ADRA2A—attention deficit hyperactivity disorder	0.0132	0.0315	CbGpPWpGaD
Dabigatran etexilate—CES2—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.0127	0.0304	CbGpPWpGaD
Dabigatran etexilate—CES2—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.0113	0.0271	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.0107	0.0257	CbGpPWpGaD
Dabigatran etexilate—ABCB1—forebrain—attention deficit hyperactivity disorder	0.0105	0.018	CbGeAlD
Dabigatran etexilate—ABCB1—cardiovascular system—attention deficit hyperactivity disorder	0.00885	0.0152	CbGeAlD
Dabigatran etexilate—CES1—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.00748	0.0179	CbGpPWpGaD
Dabigatran etexilate—CES2—E2F transcription factor network—EP300—attention deficit hyperactivity disorder	0.00718	0.0172	CbGpPWpGaD
Dabigatran etexilate—ABCB1—midbrain—attention deficit hyperactivity disorder	0.00691	0.0119	CbGeAlD
Dabigatran etexilate—CES1—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.00667	0.016	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00627	0.015	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00623	0.0149	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.00599	0.0143	CbGpPWpGaD
Dabigatran etexilate—ABCB1—nervous system—attention deficit hyperactivity disorder	0.00568	0.00975	CbGeAlD
Dabigatran etexilate—ABCB1—central nervous system—attention deficit hyperactivity disorder	0.00547	0.00939	CbGeAlD
Dabigatran etexilate—ABCB1—cerebellum—attention deficit hyperactivity disorder	0.00534	0.00918	CbGeAlD
Dabigatran etexilate—F2—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.00515	0.0123	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.00488	0.0117	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00454	0.0109	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00444	0.0106	CbGpPWpGaD
Dabigatran etexilate—ABCB1—brain—attention deficit hyperactivity disorder	0.00434	0.00745	CbGeAlD
Dabigatran etexilate—UGT2B7—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.0043	0.0103	CbGpPWpGaD
Dabigatran etexilate—CES1—E2F transcription factor network—EP300—attention deficit hyperactivity disorder	0.00423	0.0101	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Phase II conjugation—COMT—attention deficit hyperactivity disorder	0.00397	0.0095	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.00383	0.00917	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—SLC6A4—attention deficit hyperactivity disorder	0.00349	0.00836	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00345	0.00827	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00338	0.0081	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.00315	0.00754	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—SLC6A3—attention deficit hyperactivity disorder	0.00311	0.00745	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.00309	0.0074	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00308	0.00738	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00291	0.00697	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EP300—attention deficit hyperactivity disorder	0.00286	0.00685	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00286	0.00684	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.00284	0.00679	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00282	0.00675	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00269	0.00645	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00264	0.00633	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00256	0.00614	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.0025	0.00599	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00242	0.0058	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00238	0.00571	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00235	0.00564	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00235	0.00562	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00232	0.00556	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00232	0.00555	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.0023	0.00552	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00229	0.00548	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00219	0.00525	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.00207	0.00497	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00205	0.00491	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00195	0.00467	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00191	0.00458	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00191	0.00456	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00185	0.00442	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00181	0.00434	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00179	0.00429	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00177	0.00424	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—TPH2—attention deficit hyperactivity disorder	0.00177	0.00424	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.00177	0.00424	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—DPYD—attention deficit hyperactivity disorder	0.00174	0.00417	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.00174	0.00416	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.00167	0.004	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	0.00162	0.00389	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.00162	0.00388	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00156	0.00374	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.00154	0.00368	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—EP300—attention deficit hyperactivity disorder	0.00142	0.00341	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00142	0.00339	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—attention deficit hyperactivity disorder	0.00139	0.00334	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.00135	0.00323	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00133	0.00317	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC9A9—attention deficit hyperactivity disorder	0.00131	0.00315	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—GABRQ—attention deficit hyperactivity disorder	0.00125	0.003	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00122	0.00292	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.0012	0.00288	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00117	0.0028	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00117	0.0028	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00116	0.00277	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00108	0.00258	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—COMT—attention deficit hyperactivity disorder	0.00107	0.00257	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—MAOA—attention deficit hyperactivity disorder	0.00106	0.00255	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00105	0.00252	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00105	0.00251	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00104	0.0025	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00103	0.00246	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00103	0.00246	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00101	0.00243	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.00101	0.00241	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—EP300—attention deficit hyperactivity disorder	0.000983	0.00235	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.000978	0.00234	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—attention deficit hyperactivity disorder	0.00096	0.0023	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000949	0.00227	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.000947	0.00227	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.000944	0.00226	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—attention deficit hyperactivity disorder	0.000938	0.00225	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.000931	0.00223	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00092	0.0022	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.000857	0.00205	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000806	0.00193	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000806	0.00193	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000793	0.0019	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000737	0.00177	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.000711	0.0017	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000661	0.00158	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000655	0.00157	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000655	0.00157	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000645	0.00154	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000645	0.00154	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.000622	0.00149	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000614	0.00147	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.0006	0.00144	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000599	0.00143	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000578	0.00138	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.00056	0.00134	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—EP300—attention deficit hyperactivity disorder	0.000554	0.00133	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.00055	0.00132	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000543	0.0013	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000524	0.00125	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000506	0.00121	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000499	0.00119	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—COMT—attention deficit hyperactivity disorder	0.000488	0.00117	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000485	0.00116	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—EP300—attention deficit hyperactivity disorder	0.00046	0.0011	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC6A3—attention deficit hyperactivity disorder	0.000457	0.00109	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000435	0.00104	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—attention deficit hyperactivity disorder	0.00042	0.00101	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—COMT—attention deficit hyperactivity disorder	0.000397	0.00095	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000394	0.000944	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—EP300—attention deficit hyperactivity disorder	0.000382	0.000915	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.000355	0.000849	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000301	0.00072	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000301	0.00072	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000296	0.000708	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000275	0.000658	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.00024	0.000575	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000229	0.000548	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—EP300—attention deficit hyperactivity disorder	0.000209	0.000502	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000188	0.00045	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—COMT—attention deficit hyperactivity disorder	0.000182	0.000436	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000181	0.000433	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—EP300—attention deficit hyperactivity disorder	0.00017	0.000408	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—EP300—attention deficit hyperactivity disorder	7.81e-05	0.000187	CbGpPWpGaD
